English version
Notícias  
10 Setembro 2009
Biotecnol, Digna Biotech and Genentech enter into an Exclusive License and Option Agreement, for treatment of life-threatening liver diseases

Biotecnol and Digna Biotech announced today that they have entered into an Exclusive License and Option Agreement with Genentech, Inc. a wholly-owned member of the Roche Group, for developing and commercialising Cardiotrophin-1 for potential use in certain liver indications.

Ler mais
 PESQUISA    

Arquivo de Notícias

© 2007 APBio - Associação Portuguesa de Bioindústrias. Todos os direitos reservados.
Desenvolvido por Tektix. Powered by InstantWEB